Lawsuits against Depo‑Provera allege that brand-name and generic versions of this birth control injection may be linked to an increased risk of meningiomas, typically benign brain tumors. Plaintiffs claim Pfizer and other manufacturers failed to adequately warn users. While no jury verdicts or mass settlements have been finalized, a federal MDL was established in February 2025 and currently includes over 550 consolidated claims as of July 2025, with additional cases moving forward in state courts
A March 2024 study in the British Medical Journal reported that women using Depo‑Provera for 12 months or longer had a 5.6‑fold increased risk of meningioma.
The FDA has not required a U.S. label warning about brain‑tumor risk, despite similar warnings being added in the EU and UK
Disclaimer: This is attorney advertising. No attorney‑client relationship is formed by submitting this form or interacting with FusionByte Media, FindTheFirm, or affiliated law firms. Laws vary by state; this content is for informational purposes and not legal advice. Consult a licensed attorney in your state for advice tailored to your situation.